Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus

Molecules

Volumn 20, Issue 10, 2015, Pages 19588-19604

  Chu, Man ^a,b   Wong, Chun Kwok ^a,b   Cai, Zhe ^a,b   Dong, Jie ^a,b   Jiao, Delong ^a,b   Kam, Ngar Woon ^a,b   Lam, Christopher Wai Kei ^c   Tam, Lai Shan ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

Cytokines; IL 36; Regulatory B lymphocytes; Systemic lupus erythematosus

Indexed keywords

IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 36, HUMAN; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; INTERLEUKIN-36 RECEPTOR, HUMAN;

ADULT; B LYMPHOCYTE; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; YOUNG ADULT;

ADULT; B-LYMPHOCYTES, REGULATORY; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN; UP-REGULATION; YOUNG ADULT;

EID: 84947586744     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules201019588     Document Type: Article

References (33)

1. Mok, C.; Lau, C. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003, 56, 481-490.
2. Wong, C.K.; Ho, C.Y.; Li, E.K.; Lam, C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9, 589-593.
3. Wong, C.K.; Li, E.K.; Ho, C.Y.; Lam, C.W. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000, 39, 1078-1081.
4. Wong, C.K.; Lit, L.C.; Tam, L.S.; Li, E.K.; Wong, P.T.; Lam, C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 2008, 127, 385-393.
5. Lit, L.C.; Wong, C.K.; Li, E.K.; Tam, L.S.; Lam, C.W. Elevated plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2006, 65, 209-215.
6. Rönnblom, L.; Elkon, K.B. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 2010, 6, 339-347.
7. Park, Y.B.; Lee, S.K.; Kim, D.S.; Lee, J.; Lee, C.H.; Song, C.H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 1998, 16, 283-288.
8. Dunn, E.; Sims, J.E.; Nicklin, M.J.; O'Neill, L.A. Annotating genes with potential roles in the immune system: Six new members of the IL-1 family. Trends Immunol. 2001, 22, 533-536.
9. Smith, D.E.; Renshaw, B.R.; Ketchem, R.R.; Kubin, M.; Garka, K.E.; Sims, J.E. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 2000, 275, 1169-1175.
10. Towne, J.E.; Garka, K.E.; Renshaw, B.R.; Virca, G.D.; Sims, J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 2004, 279, 13677-13688.
11. Gresnigt, M.S.; van de Veerdonk, F.L. Biology of IL-36 cytokines and their role in disease. Semin. Immunol. 2013, 25, 458-465.
12. Tortola, L.; Rosenwald, E.; Abel, B.; Blumberg, H.; Schafer, M.; Coyle, A.J.; Renauld, J.C.; Werner, S.; Kisielow, J.; Kopf, M. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Investig. 2012, 122, 3965-3976.
13. Johnston, A.; Xing, X.; Guzman, A.M.; Riblett, M.; Loyd, C.M.; Ward, N.L.; Wohn, C.; Prens, E.P.; Wang, F.; Maier, L.E.; et al. IL-1F5, -F6, -F8, and -F9: A novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 2011, 186, 2613-2622.
14. Carrier, Y.; Ma, H.L.; Ramon, H.E.; Napierata, L.; Small, C.; O'Toole, M.; Young, D.A.; Fouser, L.A.; Nickerson-Nutter, C.; Collins, M.; et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis. J. Investig. Dermatol. 2011, 131, 2428-2437.
15. Vigne, S.; Palmer, G.; Martin, P.; Lamacchia, C.; Strebel, D.; Rodriguez, E.; Olleros, M.L.; Vesin, D.; Garcia, I.; Ronchi, F.; et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012, 120, 3478-3487.
16. Vigne, S.; Palmer, G.; Lamacchia, C.; Martin, P.; Talabot-Ayer, D.; Rodriguez, E.; Ronchi, F.; Sallusto, F.; Dinh, H.; Sims, J.E.; et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118, 5813-5823.
17. Kalampokis, I.; Yoshizaki, A.; Tedder, T.F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 2013, 15, S1.
18. Mauri, C.; Blair, P.A. Regulatory B cells in autoimmunity: Developments and controversies. Nat. Rev. Rheumatol. 2010, 6, 636-643.
19. Blair, P.A.; Norena, L.Y.; Flores-Borja, F.; Rawlings, D.J.; Isenberg, D.A.; Ehrenstein, M.R.; Mauri, C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32, 129-140.
20. Zha, B.; Wang, L.; Liu, X.; Liu, J.; Chen, Z.; Xu, J.; Sheng, L.; Li, Y.; Chu, Y. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease. PLoS ONE 2012, 7, e49835.
21. de Masson, A.; Bouaziz, J.D.; le Buanec, H.; Robin, M.; O'Meara, A.; Parquet, N.; Rybojad, M.; Hau, E.; Monfort, J.B.; Branchtein, M.; et al. CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood 2015, 125, 1830-1839.
22. Foster, A.M.; Baliwag, J.; Chen, C.S.; Guzman, A.M.; Stoll, S.W.; Gudjonsson, J.E.; Ward, N.L.; Johnston, A. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 2014, 192, 6053-6061.
23. Towne, J.E.; Sims, J.E. IL-36 in psoriasis. Curr. Opin. Pharmacol. 2012, 12, 486-490.
24. Blumberg, H.; Dinh, H.; Dean, C., Jr.; Trueblood, E.S.; Bailey, K.; Shows, D.; Bhagavathula, N.; Aslam, M.N.; Varani, J.; Towne, J.E.; et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J. Immunol. 2010, 185, 4354-4362.
25. Ciccia, F.; Accardo-Palumbo, A.; Alessandro, R.; Alessandri, C.; Priori, R.; Guggino, G.; Raimondo, S.; Carubbi, F.; Valesini, G.; Giacomelli, R.; et al. Interleukin-36alpha axis is modulated in patients with primary Sjogren's syndrome. Clin. Exp. Immunol. 2015, 181, 230-238.
26. Lamacchia, C.; Palmer, G.; Rodriguez, E.; Martin, P.; Vigne, S.; Seemayer, C.A.; Talabot-Ayer, D.; Towne, J.E.; Gabay, C. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis. Res. Ther. 2013, 15, R38.
27. Dietrich, D.; Gabay, C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat. Rev. Rheumatol. 2014, 10, 639-640.
28. Frey, S.; Derer, A.; Messbacher, M.E.; Baeten, D.L.; Bugatti, S.; Montecucco, C.; Schett, G.; Hueber, A.J. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann. Rheum. Dis. 2013, 72, 1569-1574.
29. Zhang, M.; Xu, W.D.; Zhu, Y.; Wen, P.F.; Leng, R.X.; Pan, H.F.; Ye, D.Q. Serum levels of cytokines in systemic lupus erythematosus. Z. Rheumatol. 2014, 73, 277-280.
30. Nguyen, T.T.; Niyonsaba, F.; Ushio, H.; Akiyama, T.; Kiatsurayanon, C.; Smithrithee, R.; Ikeda, S.; Okumura, K.; Ogawa, H. Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-?B. J. Dermatol. Sci. 2012, 68, 63-66.
31. Magne, D.; Palmer, G.; Barton, J.L.; Mezin, F.; Talabot-Ayer, D.; Bas, S.; Duffy, T.; Noger, M.; Guerne, P.A.; Nicklin, M.J.; et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther. 2006, 8, R80.
32. Towne, J.E.; Renshaw, B.R.; Douangpanya, J.; Lipsky, B.P.; Shen, M.; Gabel, C.A.; Sims, J.E. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011, 286, 42594-42602.
33. Tan, E.M.; Cohen, A.S.; Fries, J.F.; Masi, A.T.; Mcshane, D.J.; Rothfield, N.F.; Schaller, J.G.; Talal, N.; Winchester, R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25, 1271-1277.